4-Hydroxy-4--2-<3-methoxy-benzyliden>-buten-(3)-saeurelacton | 108368-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Hydroxy-4--2-<3-methoxy-benzyliden>-buten-(3)-saeurelacton
• 英文别名: (3E)-3-(3-methoxybenzylidene)-5-(4-methylphenyl)furan-2(3H)-one；(3E)-3-[(3-methoxyphenyl)methylidene]-5-(4-methylphenyl)furan-2-one
• CAS: 108368-39-4
• 化学式: C₁₉H₁₆O₃
• 分子量: 292.334
• InChiKey: ZASAIMSBBRRWMC-MHWRWJLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Hydroxy-4--2-<3-methoxy-benzyliden>-buten-(3)-saeurelacton 、 乙酰乙酸乙酯 反应 0.17h， 生成
  参考文献：
  名称：

  Reactions of 5-aryl-3-arylmethylene substituted 3H-furan-2-ones and 3H-pyrrol-2-ones with acetoacetic ester

  摘要：

  The title reactions afforded ethyl 4-(arylmethylene)-6-oxo-2-aryl-4,5,6,7-tetrahydrobenzofuran-5-carboxylates and ethyl 4-(arylmethylene)-6-oxo-2-aryl-4,5,6,7-tetrahydro-1H-indole-5-carboxylates the structures of which were confirmed by IR and (1)H NMR spectroscopy.

  DOI：

  10.1016/j.mencom.2008.05.019

文献信息

• NEW METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASES ASSOCIATED WITH BONE LOSS
  申请人：Centre National de la Recherche Scientifique (CNRS)

  公开号：EP2331967B1

  公开（公告）日：2015-11-04
• Compounds for treating and/or preventing diseases associated with bone loss
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-

  公开号：EP2716285B1

  公开（公告）日：2016-04-27
• JP2012500393A
  申请人：——

  公开号：JP2012500393A

  公开（公告）日：2012-01-05
• METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING AND/OR PREVENTING DISEASE-ASSOCIATED BONE LOSS
  申请人：Blangy Anne

  公开号：US20110212974A1

  公开（公告）日：2011-09-01

  The present invention concerns a method for identifying a compound which inhibits the activation of RAC GTPase by DOCK5 protein comprising the steps of (i) coexpressing the DOCK5 and the RAC proteins in a cell, wherein said DOCK5 protein induces the conversion of inactive RAC, which inactive RAC is bound to GDP, to active RAC, which active RAC is bound to GTP, (ii) contacting or not said cell with said compound, (iii) determining the conversion of inactive RAC to active RAC in the presence or absence of said compound, and (iv) selecting the compound inhibiting the conversion of inactive RAC to active RAC. Said compound is useful for treating disease-associated bone loss.
• US9091678B2
  申请人：——

  公开号：US9091678B2

  公开（公告）日：2015-07-28